Article
Oncology
Sisi Wang, Lijun Peng, Wenqian Xu, Yuebo Zhou, Ziyan Zhu, Yushan Kong, Stewart Leung, Jin Wang, Xiaoqiang Yan, Jian-Qing Mi
Summary: The newly designed antibodies A-319 and A-2019 showed potent antitumor effects in vitro, ex vivo, and in vivo experiments. A-319 and A-2019 are CD3/CD19 and CD3/CD19/CD20 bispecific and trispecific antibodies, respectively, capable of recruiting T cells, enhancing T-cell function, mediating B-cell depletion, and inhibiting tumor growth.
FRONTIERS OF MEDICINE
(2022)
Review
Oncology
Linus Angenendt, Jan-Henrik Mikesch, Christoph Schliemann
Summary: The development of antibody-based therapeutics for patients with acute myeloid leukemia has been challenging due to the shared expression of antigens on leukemic blasts and hematopoietic stem and progenitor cells. However, recent years have seen the approval of the first antibody-drug conjugate for AML treatment, and promising results from other antibody-based therapeutics in clinical trials.
CANCER TREATMENT REVIEWS
(2022)
Review
Pharmacology & Pharmacy
Wei Li, Yayu Zhang, Ranjith Kumar Kankala, Liang Zou, Zhoujiang Chen
Summary: This review highlights the mechanisms and application status of innovative antibody and cellular-based therapies for pediatric acute lymphoblastic leukemia (ALL), and discusses the significant prospects and challenges.
Review
Oncology
Francesco Tamiro, Andrew P. Weng, Vincenzo Giambra
Summary: Leukemia-initiating cells (LIC) are unique cells in different types of leukemia that have self-renewing capabilities and produce tumors, which are functionally distinct from bulk leukemia cells. Current conventional treatments are not effective in eliminating LICs, hence innovative therapeutics targeting LICs hold promise for developing an effective cure for ALL.
Review
Biochemistry & Molecular Biology
Anca Viorica Ivanov, Mirabela Smaranda Alecsa, Roxana Popescu, Magdalena Iuliana Starcea, Adriana Maria Mocanu, Cristina Rusu, Ingrith Crenguta Miron
Summary: In the past 40 years, the survival rate for pediatric cancer has greatly improved, reaching 75-80%. However, leukemia still remains a major cause of morbidity and mortality in specific patient populations. The future of leukemia treatment lies in molecular therapies, immune therapy, and cellular therapy. Recent advances in the field have led to the development of novel therapies for childhood leukemia, including targeted therapies and immunotherapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Sargam Kapoor, Grace Champion, Aparna Basu, Anu Mariampillai, Matthew J. Olnes
Summary: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies arising from the bone marrow with poor prognosis. Recent advancements in immune therapies, including immune suppressive therapy and novel treatments like monoclonal antibodies and cellular therapeutics, have shown promise in treating these diseases.
Review
Oncology
Chun-fung Sin, Pui-hei Marcus Man
Summary: ETP-ALL, a distinct subtype of T-ALL, has poor prognosis and limited novel therapy options. Diagnosing and managing ETP-ALL remains challenging, despite advances in understanding its molecular mechanisms. Risk-adapted therapy and allogenic stem cell transplant play an emerging role in improving patient outcomes, with potential novel therapies proposed based on current knowledge.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Roberto Limongello, Andrea Marra, Antonella Mancusi, Samanta Bonato, Eni Hoxha, Loredana Ruggeri, Susanta Hui, Andrea Velardi, Antonio Pierini
Summary: Adverse genetic risk acute myeloid leukemia (AML) poses a significant treatment challenge with poor outcomes, necessitating novel therapeutic approaches. While allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the curative option, high relapse rates and dismal outcomes prompt the exploration of new transplant strategies. Recent research has shown that haploidentical allo-HSCT combined with T cell adoptive immunotherapy can overcome chemoresistance and improve survival in AML patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Anna Aureli, Beatrice Marziani, Adriano Venditti, Tommaso Sconocchia, Giuseppe Sconocchia
Summary: The emergence of targeted therapies has revolutionized the management of B-lineage acute lymphoblastic leukemia, allowing for optimism in replacing traditional treatments. However, few patients currently benefit from these therapies, necessitating further research to improve outcomes, particularly in patients resistant to current treatments. This review discusses new therapeutic options, including bispecific antibodies, antibody-drug conjugates, and CAR-based therapies.
Article
Oncology
Soyoung Park, Ali H. Abdel Sater, Johannes F. Fahrmann, Ehsan Irajizad, Yining Cai, Hiroyuki Katayama, Jody Vykoukal, Makoto Kobayashi, Jennifer B. Dennison, Guillermo Garcia-Manero, Charles G. Mullighan, Zhaohui Gu, Marina Konopleva, Samir Hanash
Summary: This study provides evidence for the overexpression of UHRF1 in acute lymphocytic leukemia (ALL) and reveals its direct interaction with c-Myc to regulate its expression, facilitating ALL cell growth through the cMYC-CDK4/6-phosphoRb signaling pathway. Analysis of human leukemia transcriptomic datasets shows concordant overexpression of UHRF1 in B-Cell and T-Cell ALL, suggesting its potential as a therapeutic target in ALL.
Article
Multidisciplinary Sciences
Yizhen Li, Takaya Moriyama, Satoshi Yoshimura, Xujie Zhao, Zhenhua Li, Xu Yang, Elisabeth Paietta, Mark R. Litzow, Marina Konopleva, Jiyang Yu, Hiroto Inaba, Raul C. Ribeiro, Ching-Hon Pui, Jun J. Yang
Summary: This study identified previously unknown genetic mechanisms of resistance to blinatumomab in B cell acute lymphoblastic leukemia. Loss of CD58 and a specific mutation in the PAX5 gene were associated with resistance. These findings provide strategies for personalized treatment.
Review
Immunology
Mohammad Hassan Hodroj, Iman Abou Dalle, Nour Moukalled, Jean El Cheikh, Mohamad Mohty, Ali Bazarbachi
Summary: The outcome of B-cell acute lymphoblastic leukemia has improved with multi-agent chemotherapy and immunotherapeutic agents. However, relapse post-transplant is still common. This review discusses strategies such as tyrosine kinase inhibitors, innovative agents, and cellular therapy to prevent and overcome relapse post allo-HCT in ALL patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, Research & Experimental
Martina Quattrone, Alessia Di Pilla, Livio Pagano, Luana Fianchi
Summary: Infections are common complications during the treatment of Acute Lymphoblastic Leukemia (ALL), with almost half of the patients developing infectious events during induction. The use of new monoclonal and bispecific antibodies and CAR-T therapy has the potential to improve overall survival and disease-free survival of patients with ALL and may also impact the epidemiology of infections in this population. This review focused on the infectious complications of Blinatumomab, Inotuzumab, Rituximab, and CAR-T therapy in both adult and pediatric ALL patients, highlighting the unique infection patterns observed in CAR-T patients.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Andreas Viardot, Elisa Sala
Summary: The anti-CD19 immunotherapy has shown significant potential for treating B-precursor acute lymphoblastic leukemia (B-ALL), with major advances in CD19 monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engaging antibodies and adoptive cellular therapies such as CAR-Ts. Experimental anti-CD19 antibodies or CAR-Ts may overcome limitations of toxicity, rapid clearance, or resistance, suggesting promising results for novel cellular constructs.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Cell Biology
Panpan Chen, Guanfei Gao, Yuanlin Xu, Peijun Jia, Yan Li, Yating Li, Jiaming Cao, Jiangfeng Du, Shijie Zhang, Jingxin Zhang
Summary: In this study, we constructed a prognostic model for acute lymphoblastic leukemia (ALL) by identifying important genes closely related to ALL prognosis. The model can help clinicians predict the prognosis of ALL patients and adjust the treatment plan accordingly.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)